Bicifadine

Bicifadine
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
Biological half-life 1.6 hours
Excretion renal
Identifiers
CAS Number 71195-57-8 YesY
PubChem (CID) 47953
ChemSpider 9889978 YesY
UNII B0SV3N7J3H YesY
ChEMBL CHEMBL511099 N
Chemical and physical data
Formula C12H15N
Molar mass 173.25 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth.[1][2][3]

In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain.[4][5][6] XTL ran a PhaseIIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008;[7] XTL terminated the agreement in 2010.[8] In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.[9]

Bicifadine has a non-opioid, non-NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs.[10] While the drug is purported to be a serotonin (SERT) and noradrenaline transporter (NET) inhibitor, it also has effects at the dopamine transporter (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or "triple reuptake inhibitor."[11]

See also

References

  1. ↑ Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig. 2008 Sep;5(3):142-7. PMID 20046357 PMC2796030
  2. ↑ [http://www.sec.gov/Archives/edgar/data/1066833/000114420404018172/v08017_ex10-51.txt SEC Filing: Wyeth-DOV Restated License Agreement Page accessed July 15, 2015]
  3. ↑ Neubauer, DN. "Indiplon". pp 453-464 in GABA and Sleep: Molecular, Functional and Clinical Aspects. Eds Jaime M. Monti, Seithikurippu Ratnas Pandi-Perumal, Hanns Möhler. Springer Science & Business Media, 2010 ISBN 9783034602266
  4. ↑ BioCentury, July 26, 2010
  5. ↑ "Euthymics: Balancing act" (PDF). BioCentury, The Bernstein Report on Biobusiness. December 5, 2011. p. A13.
  6. ↑ John Caroll for Fierce Biotech. Jan 07, 2007 XTL licenses development rights to pain therapy
  7. ↑ Fierce Biotech. December 9, 2008 Tiny XTL cuts costs, jobs
  8. ↑ XTL Form 6-K March, 2013
  9. ↑ Fierce Biotech July 22, 2010 Euthymics lands $24M to fund antidepressant work
  10. ↑ Wang, R. I.; Johnson, R. P.; Lee, J. C.; Waite, E. M. (1982). "The Oral Analgesic Efficacy of Bicifadine Hydrochloride in Postoperative Pain". Journal of Clinical Pharmacology. 22 (4): 160–164. doi:10.1002/j.1552-4604.1982.tb02157.x. PMID 7096604.
  11. ↑ Basile, A.; Janowsky, A.; Golembiowska, K.; Kowalska, M.; Tam, E.; Benveniste, M.; Popik, P.; Nikiforuk, A.; Krawczyk, M.; Nowak, G.; Krieter, P. A.; Lippa, A. S.; Skolnick, P.; Koustova, E. (2007). "Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1208–1225. doi:10.1124/jpet.106.116483. PMID 17325229.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.